4DMT streamlines to accelerate phase 3 wet AMD program

4D Molecular Therapeutics (4DMT) announced the acceleration of the 4D-150 4FRONT phase 3 program in wet age-related macular degeneration (AMD), revealing that it has offset expected expenses by “streamlining operations.”

The California-based biotech implemented a workforce reduction of approximately 25% this month, primarily in the areas supporting early-stage R&D and support functions. The workforce reduction is expected to provide annual cost savings of approximately $15 million and offsets additional expenses expected based on the accelerated timelines for the 4FRONT clinical trials and BLA preparation, supporting the company’s cash runway into 2028.

According to 4DMT, initial enrollment and site activation for 4FRONT-1, the North American phase 3 clinical trial of 4D-150 in wet AMD, have exceeded initial projections, with 52-week topline data now expected in H1 2027. The second phase 3 trial, 4FRONT-2, was initiated ahead of schedule in June 2025, with 52-week topline data expected in H2 2027.

4D-150 is a retinal gene therapy that uses a proprietary vector, R100, to deliver a dual-transgene payload that expresses both aflibercept (the active ingredient in Regeneron’s Eylea) and an RNAi molecule targeting VEGF-C. It is designed to provide multi-year sustained delivery of anti-VEGF from the retina with a single, safe, intravitreal injection.

Wet AMD, the rarer form of AMD, is a type of macular degeneration in which abnormal blood vessels grow into the macula, the central area of the retina. It is a leading cause of irreversible vision loss or blindness in the U.S. and Europe, especially if left untreated.